

Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)

Meeting – November 14, 2018 @ 4:00pm

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

A. Acknowledgment of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

A. October 10, 2018 DUR Minutes – Vote

B. October 10, 2018 DUR Recommendations Memorandum

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

**4. Update on Medication Coverage Authorization Unit/2018 Fall Pipeline Update
– See Appendix B**

A. Medication Coverage Activity for October 2018

B. Pharmacy Helpdesk Activity for October 2018

C. 2018 Fall Pipeline Update

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

**5. Action Item – Vote to Prior Authorize Ilumya™ (Tildrakizumab-asmn) and Olumiant® (Baricitinib)
– See Appendix C**

A. Introduction

B. College of Pharmacy Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

**6. Action Item – Vote to Prior Authorize Triptodur® (Triptorelin) and Orilissa™ (Elagolix)
– See Appendix D**

A. Introduction

B. College of Pharmacy Recommendations

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Medina, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Yescarta® (Axicabtagene) and to Update the Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML) Medications Approval Criteria – See Appendix E

A. Introduction

B. Recommendations

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Medina, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Braftovi™ (Encorafenib), Mektovi® (Binimetinib), and Libtayo® (Cemiplimab-rwlc) – See Appendix F

A. Introduction

B. Recommendations

Items to be presented by Dr. Ratterman, Dr. Muchmore, Chairman:

9. Annual Review of Factor Replacement Products and 30-Day Notice to Prior Authorize Hemlibra[®] (Emicizumab-kxwh), Feiba[®] (Anti-Inhibitor Coagulant Complex), Novoseven[®] RT [Coagulation Factor VIIa (Recombinant)], and Jivi[®] [Antihemophilic Factor (Recombinant), PEGylated-aucl] – See Appendix G

- A. Current Prior Authorization Criteria
- B. Utilization of Factor Replacement Products
- C. Prior Authorization of Factor Replacement Products
- D. Market News and Updates
- E. Inhibitors and Treatment
- F. Hemlibra[®] (Emicizumab-kxwh) Product Summary
- G. Jivi[®] [Antihemophilic Factor (Recombinant), PEGylated-aucl] Product Summary
- H. Recommendations
- I. Utilization Details of Factor Replacement Products

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

10. Action Item – Vote to Prior Authorize Nocdurna[®] (Desmopressin Acetate Sublingual Tablet) – See Appendix H

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Connell, Dr. Muchmore, Chairman:

11. Action Item – Vote to Prior Authorize Krystexxa[®] (Pegloticase) – See Appendix I

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

12. Action Item – Vote to Prior Authorize Impoysz[™] (Clobetasol Propionate 0.025% Cream) – See Appendix J

- A. Introduction
- B. Market News and Updates
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

13. Annual Review of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators and 30-Day Notice to Prior Authorize Symdeko[®] (Tezacaftor/Ivacaftor) and Orkambi[®] (Lumacaftor/Ivacaftor Oral Granules) – See Appendix K

- A. Current Prior Authorization Criteria
- B. Utilization of CFTR Modulators
- C. Prior Authorization of CFTR Modulators
- D. Market News and Updates
- E. Symdeko[®] (Tezacaftor/Ivacaftor) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of CFTR Modulators

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

14. 30-Day Notice to Prior Authorize Onpattro[™] (Patisiran) and Tegsedi[™] (Inotersen) – See Appendix L

- A. Introduction
- B. Onpattro[™] (Patisiran) Product Summary
- C. Tegsedi[™] (Inotersen) Product Summary
- D. Market News and Updates
- E. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

15. Annual Review of Various Systemic Antibiotics and 30-Day Notice to Prior Authorize Zemdri™ (Plazomicin), Xerava™ (Eravacycline), Nuzyra™ (Omadacycline), Seysara™ (Sarecycline), and Ximino™ (Minocycline Extended-Release) – See Appendix M

- A. Current Prior Authorization Criteria
- B. Utilization of Various Systemic Antibiotics
- C. Prior Authorization of Various Systemic Antibiotics
- D. Market News and Updates
- E. Product Summaries
- F. Cost Comparison
- G. College of Pharmacy Recommendations
- H. Utilization Details of Various Systemic Antibiotics

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

16. Annual Review of Hepatitis C Medications – See Appendix N

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Hepatitis C Summary Statistics for Treated Members
- D. Trends of Hepatitis C Medication Utilization
- E. Utilization of Hepatitis C Medications
- F. Prior Authorization of Hepatitis C Medications
- G. Market News and Updates
- H. Regimen Comparison
- I. College of Pharmacy Recommendations
- J. Utilization Details of Hepatitis C Medications

Items to be presented by Dr. Connell, Dr. Muchmore, Chairman:

17. 30-Day Notice to Prior Authorize Signifor® LAR (Pasireotide) – See Appendix O

- A. Acromegaly Summary
- B. Cushing's Disease Summary
- C. Market News and Updates
- D. Signifor® LAR (Pasireotide) Product Summary
- E. College of Pharmacy Recommendations

Non-Presentation; Questions Only:

18. Industry News and Updates – See Appendix P

- A. Introduction
- B. News and Updates

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

19. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix Q

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

20. Future Business* (Upcoming Product and Class Reviews)

- A. Maintenance Asthma and Chronic Obstructive Pulmonary Disease (COPD) Medications
- B. Thrombocytopenia Medications
- C. Inhaled Anti-infective Medications
- D. Muscular Dystrophy Medications

**Future business subject to change.*

21. Adjournment